AbCellera Biologics (ABCL) Competitors $2.97 +0.03 (+1.02%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABCL vs. PTCT, RNA, RYTM, IMVT, MLTX, ACAD, VCEL, XENE, MOR, and SWTXShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Immunovant (IMVT), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. PTC Therapeutics Avidity Biosciences Rhythm Pharmaceuticals Immunovant MoonLake Immunotherapeutics ACADIA Pharmaceuticals Vericel Xenon Pharmaceuticals MorphoSys SpringWorks Therapeutics AbCellera Biologics (NASDAQ:ABCL) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends. Do analysts rate ABCL or PTCT? AbCellera Biologics presently has a consensus target price of $8.33, suggesting a potential upside of 180.58%. PTC Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 25.46%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe AbCellera Biologics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67PTC Therapeutics 3 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47 Which has stronger earnings & valuation, ABCL or PTCT? AbCellera Biologics has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$32.96M26.61-$146.40M-$0.61-4.87PTC Therapeutics$937.82M3.61-$626.60M-$5.94-7.38 Does the MarketBeat Community believe in ABCL or PTCT? PTC Therapeutics received 508 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.06% of users gave AbCellera Biologics an outperform vote while only 61.89% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformAbCellera BiologicsOutperform Votes5476.06% Underperform Votes1723.94% PTC TherapeuticsOutperform Votes56261.89% Underperform Votes34638.11% Which has more volatility & risk, ABCL or PTCT? AbCellera Biologics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ABCL or PTCT? 61.4% of AbCellera Biologics shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ABCL or PTCT? In the previous week, PTC Therapeutics had 13 more articles in the media than AbCellera Biologics. MarketBeat recorded 20 mentions for PTC Therapeutics and 7 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.47 beat PTC Therapeutics' score of 0.31 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ABCL or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to AbCellera Biologics' net margin of -533.32%. PTC Therapeutics' return on equity of 0.00% beat AbCellera Biologics' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-533.32% -15.73% -12.22% PTC Therapeutics -50.32%N/A -16.44% SummaryAbCellera Biologics beats PTC Therapeutics on 11 of the 19 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$877.24M$6.58B$5.35B$9.07BDividend YieldN/A2.95%5.13%4.02%P/E Ratio-4.879.8389.4817.34Price / Sales26.61307.681,252.31134.70Price / CashN/A61.4443.7535.97Price / Book0.756.055.324.80Net Income-$146.40M$154.62M$122.60M$224.91M7 Day Performance1.71%-1.70%0.88%1.90%1 Month Performance10.41%2.75%4.81%5.08%1 Year Performance-42.77%2.60%27.90%21.15% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.7226 of 5 stars$2.97+1.0%$8.33+180.6%-43.6%$877.24M$32.96M-4.87500Gap UpPTCTPTC Therapeutics4.4915 of 5 stars$44.74+1.8%$54.08+20.9%+56.0%$3.45B$900.66M-7.531,410Analyst ForecastAnalyst RevisionRNAAvidity Biosciences2.0328 of 5 stars$28.43-3.5%$65.80+131.4%+169.0%$3.39B$10.12M-9.87190RYTMRhythm Pharmaceuticals4.084 of 5 stars$55.00-2.1%$68.09+23.8%+30.7%$3.38B$112.53M-12.70140IMVTImmunovant1.9921 of 5 stars$23.01-2.0%$47.22+105.2%-41.7%$3.38BN/A-10.36120Analyst ForecastInsider TradeNews CoverageMLTXMoonLake Immunotherapeutics1.9666 of 5 stars$46.23-0.2%$81.43+76.1%-22.3%$2.95BN/A-35.842Analyst UpgradeNews CoverageACADACADIA Pharmaceuticals4.0028 of 5 stars$17.64+2.2%$25.25+43.1%-37.2%$2.94B$929.24M22.62510Short Interest ↑News CoverageVCELVericel1.7654 of 5 stars$59.21-0.5%$61.14+3.3%+56.1%$2.92B$226.84M987.00300Analyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals2.7019 of 5 stars$38.31-0.3%$56.00+46.2%-15.6%$2.92B$9.43M-13.59251News CoveragePositive NewsMORMorphoSys0.215 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics1.6334 of 5 stars$37.71-12.3%$70.00+85.6%-13.8%$2.81B$135.49M-9.72230Analyst RevisionNews Coverage Related Companies and Tools Related Companies PTC Therapeutics Competitors Avidity Biosciences Competitors Rhythm Pharmaceuticals Competitors Immunovant Competitors MoonLake Immunotherapeutics Competitors ACADIA Pharmaceuticals Competitors Vericel Competitors Xenon Pharmaceuticals Competitors MorphoSys Competitors SpringWorks Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABCL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
